Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes

2011 ◽  
Vol 121 (3) ◽  
pp. 67-72 ◽  
Author(s):  
Paweł Samborski ◽  
Dariusz Naskręt ◽  
Aleksandra Araszkiewicz ◽  
Paweł Niedźwiecki ◽  
Dorota Zozulińska‑Ziółkiewicz ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Skin Autofluorescence ◽  
Advanced Glycation ◽  
Advanced Glycation End Product ◽  
Product Accumulation

The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes

Diabetes Care ◽  
1998 ◽  
Vol 21 (11) ◽  
pp. 1997-2002 ◽  
Author(s):  
T. J. Berg ◽  
J. T. Clausen ◽  
P. A. Torjesen ◽  
K. Dahl-Jorgensen ◽  
H. J. Bangstad ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Children And Adolescents ◽  
Advanced Glycation ◽  
Advanced Glycation End Product ◽  
Carboxymethyl Lysine

scholarly journals Advanced glycation end products are associated with arterial stiffness in type 1 diabetes

2014 ◽  
Vol 221 (3) ◽  
pp. 405-413 ◽  
Author(s):  
Gemma Llauradó ◽  
Victòria Ceperuelo-Mallafré ◽  
Carme Vilardell ◽  
Rafael Simó ◽  
Pilar Gil ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 1 Diabetes ◽  
Cardiovascular Risk ◽  
Cardiovascular Events ◽  
Skin Autofluorescence ◽  
Serum Concentrations ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

The aim of this study was to investigate the relationship between advanced glycation end products (AGEs) and arterial stiffness (AS) in subjects with type 1 diabetes without clinical cardiovascular events. A set of 68 patients with type 1 diabetes and 68 age- and sex-matched healthy subjects were evaluated. AGEs were assessed using serum concentrations ofN-carboxy-methyl-lysine (CML) and using skin autofluorescence. AS was assessed by aortic pulse wave velocity (aPWV), using applanation tonometry. Patients with type 1 diabetes had higher serum concentrations of CML (1.18 vs 0.96 μg/ml;P=0.008) and higher levels of skin autofluorescence (2.10 vs 1.70;P<0.001) compared with controls. These differences remained significant after adjustment for classical cardiovascular risk factors. Skin autofluorescence was positively associated with aPWV in type 1 diabetes (r=0.370;P=0.003). No association was found between CML and aPWV. Skin autofluorescence was independently and significantly associated with aPWV in subjects with type 1 diabetes (β=0.380;P<0.001) after adjustment for classical cardiovascular risk factors. Additional adjustments for HbA1c, disease duration, and low-grade inflammation did not change these results. In conclusion, skin accumulation of autofluorescent AGEs is associated with AS in subjects with type 1 diabetes and no previous cardiovascular events. These findings indicate that determination of tissue AGE accumulation may be a useful marker for AS in type 1 diabetes.

scholarly journals Advanced glycation end products as predictors of renal function in youth with type 1 diabetes

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Josephine M. Forbes ◽  
Selena Le Bagge ◽  
Samuel Righi ◽  
Amelia K. Fotheringham ◽  
Linda A. Gallo ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Kidney Function ◽  
Early Adulthood ◽  
Diabetes Duration ◽  
Skin Autofluorescence ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Blood Glucose Concentrations

AbstractTo examine if skin autofluorescence (sAF) differed in early adulthood between individuals with type 1 diabetes and age-matched controls and to ascertain if sAF aligned with risk for kidney disease. Young adults with type 1 diabetes (N = 100; 20.0 ± 2.8 years; M:F 54:46; FBG-11.6 ± 4.9 mmol/mol; diabetes duration 10.7 ± 5.2 years; BMI 24.5(5.3) kg/m2) and healthy controls (N = 299; 20.3 ± 1.8 years; M:F-83:116; FBG 5.2 ± 0.8 mmol/L; BMI 22.5(3.3) kg/m2) were recruited. Skin autofluorescence (sAF) and circulating AGEs were measured. In a subset of both groups, kidney function was estimated by GFRCKD-EPI CysC and uACR, and DKD risk defined by uACR tertiles. Youth with type 1 diabetes had higher sAF and BMI, and were taller than controls. For sAF, 13.6% of variance was explained by diabetes duration, height and BMI (Pmodel = 1.5 × 10–12). In the sub-set examining kidney function, eGFR and sAF were higher in type 1 diabetes versus controls. eGFR and sAF predicted 24.5% of variance in DKD risk (Pmodel = 2.2 × 10–9), which increased with diabetes duration (51%; Pmodel < 2.2 × 10–16) and random blood glucose concentrations (56%; Pmodel < 2.2 × 10–16). HbA1C and circulating fructosamine albumin were higher in individuals with type 1 diabetes at high versus low DKD risk. eGFR was independently associated with DKD risk in all models. Higher eGFR and longer diabetes duration are associated with DKD risk in youth with type 1 diabetes. sAF, circulating AGEs, and urinary AGEs were not independent predictors of DKD risk. Changes in eGFR should be monitored early, in addition to uACR, for determining DKD risk in type 1 diabetes.

Sign in / Sign up

Export Citation Format

Share Document